Journal scan

Potential cardiovascular benefits of canagliflozin compared with other diabetes drugs

Blood pressure

Medications for type 2 diabetes have different modes of action. The various non-gliflozin drugs work by stimulating production of insulin, reducing glucagon which increases blood sugar levels or enhancing the action of insulin in the body.

Canagliflozin, by contrast, is a sodium-glucose co-transporter inhibitor, which means that it lowers blood sugar levels by blocking the reabsorption of glucose in the kidneys. When combined with a healthy lifestyle, these drugs have been shown to promote weight loss and regulate blood pressure and other cardiovascular markers as well as improving glycaemic control.

Cardiovascular disease is a leading cause of morbidity and mortality in patients with type 2 diabetes. In addition to atherosclerotic heart disease, patients are at increased risk of being admitted to hospital or dying with heart failure. Despite early indication of benefit, until


Want to read more?

Unlock full access to RCNi Plus today

Save over 50% on your first three months:

  • Customisable clinical dashboard featuring 200+ topics
  • Unlimited online access to all 10 RCNi Journals including Nursing Older People
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • NMC-compliant RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests

This article is not available as part of an institutional subscription. Why is this?